Latest News in the pharma Industry

Research & Development

Xigen’s innovative JNK inhibitor, Brimapitide, delivers positive Phase II results in inflammatory eye disease

Xigen’s innovative JNK inhibitor, Brimapitide, delivers positive Phase II results in inflammatory eye disease

5 Jan 2017

The company's long-acting therapeutic peptides are designed to allow the efficient delivery of the active element to intracellular targets.

Read more 
Corbus Pharmaceuticals completes Phase II study of JBT-101 for the treatment of cystic fibrosis

Corbus Pharmaceuticals completes Phase II study of JBT-101 for the treatment of cystic fibrosis

1 Jan 2017

Resunab is designed to resolve inflammation thus having the potential to provide significant clinical benefit to CF patients, importantly without immunosuppression.

Read more 
PharmaCyte Biotech’s cannabinoid therapy may offer potential for childhood brain cancers

PharmaCyte Biotech’s cannabinoid therapy may offer potential for childhood brain cancers

1 Jan 2017

Reported research continues to demonstrate the anti-cancer properties of cannabinoids.

Read more 
NIPTE is partner in newly announced National Biopharmaceutical Manufacturing Institute

NIPTE is partner in newly announced National Biopharmaceutical Manufacturing Institute

31 Dec 2016

The participating NIPTE team will primarily focus on biopharmaceutical formulations and product development, and FDA regulatory science.

Read more 
Bavarian Nordic initiates trial of CV301 in combination with nivolumab in patients with lung cancer

Bavarian Nordic initiates trial of CV301 in combination with nivolumab in patients with lung cancer

29 Dec 2016

Study is exploring potential benefits of combining a cancer vaccine and PD-1 checkpoint inhibitor.

Read more 
Positive Phase III results of Genentech’s investigational medicine Ocrevus

Positive Phase III results of Genentech’s investigational medicine Ocrevus

28 Dec 2016

Ocrevus is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies.

Read more 
FDA approves Shire's Adynovate

FDA approves Shire's Adynovate

28 Dec 2016

New FDA-approved indications for Adynovate provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule.

Read more 
FDA places clinical hold on several Phase I trials of Vadastuximab Talirine

FDA places clinical hold on several Phase I trials of Vadastuximab Talirine

28 Dec 2016

Six patients have been identified with hepatotoxicity, including several cases of veno-occlusive disease, with four fatal events.

Read more 
JAMA publishes Mylan and Biocon's proposed biosimilar trastuzumab Phase III data

JAMA publishes Mylan and Biocon's proposed biosimilar trastuzumab Phase III data

27 Dec 2016

Published study results showed an overall response rate of 69.6% for MYL-1401O compared to 64% for branded trastuzumab.

Read more 
Recursion receives industry awards for drug discovery platform

Recursion receives industry awards for drug discovery platform

27 Dec 2016

Computationally intelligent drug discovery platform receives two Fierce Innovation awards for Biotech Innovation and Best New Product.

Read more 
FDA approves first drug for spinal muscular atrophy

FDA approves first drug for spinal muscular atrophy

26 Dec 2016

Spinraza improved motor function in SMA patients.

Read more 
Vectura and Mundipharma sign global development programme

Vectura and Mundipharma sign global development programme

26 Dec 2016

Development and licence agreement is for pMDI inhaled triple therapy (VR2076) for asthma and COPD.

Read more